[go: up one dir, main page]

CR20130376A - Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta - Google Patents

Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta

Info

Publication number
CR20130376A
CR20130376A CR20130376A CR20130376A CR20130376A CR 20130376 A CR20130376 A CR 20130376A CR 20130376 A CR20130376 A CR 20130376A CR 20130376 A CR20130376 A CR 20130376A CR 20130376 A CR20130376 A CR 20130376A
Authority
CR
Costa Rica
Prior art keywords
ligandos
transforming
join
receiver
growth factor
Prior art date
Application number
CR20130376A
Other languages
English (en)
Inventor
Andrew Beaton
Caroline Dimech
Peter Franz Ertl
Susannah Karen Ford
Ruth Mcadam
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45444622&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130376(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of CR20130376A publication Critical patent/CR20130376A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)

Abstract

La descripcion provee un dominio variable individual de inmunoglobulina anti-TGbetaRII; convenientemente, un dominio variable individual de anti-TGFbetaRII de conformidad con la descripción.
CR20130376A 2011-01-06 2013-08-05 Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta CR20130376A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161430235P 2011-01-06 2011-01-06

Publications (1)

Publication Number Publication Date
CR20130376A true CR20130376A (es) 2013-11-29

Family

ID=45444622

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130376A CR20130376A (es) 2011-01-06 2013-08-05 Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta

Country Status (22)

Country Link
US (3) US9150651B2 (es)
EP (1) EP2661449B1 (es)
JP (2) JP6062375B2 (es)
KR (1) KR101886898B1 (es)
CN (1) CN103443126B (es)
AU (1) AU2016203609A1 (es)
BR (1) BR112013016917A2 (es)
CA (1) CA2823104A1 (es)
CL (1) CL2013001975A1 (es)
CO (1) CO6811807A2 (es)
CR (1) CR20130376A (es)
DO (1) DOP2013000162A (es)
EA (1) EA201391012A1 (es)
ES (1) ES2627299T3 (es)
IL (1) IL227254A0 (es)
MA (1) MA34820B1 (es)
MX (1) MX2013007936A (es)
PE (1) PE20140982A1 (es)
PH (1) PH12013501397A1 (es)
SG (1) SG191762A1 (es)
WO (1) WO2012093125A1 (es)
ZA (1) ZA201304726B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11644471B2 (en) 2010-09-30 2023-05-09 Ablynx N.V. Techniques for predicting, detecting and reducing aspecific protein interference in assays involving immunoglobulin single variable domains
KR101886898B1 (ko) * 2011-01-06 2018-08-08 글락소 그룹 리미티드 Ｔｇｆ-베타 수용체 ｉｉ에 결합하는 리간드
BR122017005075B1 (pt) 2011-06-23 2022-09-20 Ablynx N.V Técnicas para prever, detectar e reduzir interferência de proteína não especifica em ensaios envolvendo domínios variáveis únicos de imunoglobulina
BR112015023262B8 (pt) * 2013-03-15 2024-02-06 Ac Immune Sa Anticorpo isolado, imunoconjugado, formulação farmacêutica e usos do anticorpo
AU2014308751B2 (en) 2013-08-22 2020-03-05 Acceleron Pharma, Inc. TGF-beta receptor type II variants and uses thereof
CA2931309C (en) * 2013-11-21 2022-06-21 The Brigham And Women's Hospital, Inc. Compositions and methods for treating pulmonary hypertension
CN105873948B (zh) * 2014-01-15 2021-04-13 豪夫迈·罗氏有限公司 具有修饰的FCRN结合性质的Fc区变体
WO2016019368A1 (en) * 2014-08-01 2016-02-04 The Brigham And Women's Hospital, Inc. Methods and compositions relating to treatment of pulmonary arterial hypertension
MY193078A (en) 2015-06-24 2022-09-26 Hoffmann La Roche Anti-transferrin receptor antibodies with tailored affinity
CN108348578B (zh) 2015-08-04 2022-08-09 阿塞勒隆制药公司 用于治疗骨髓增生性病症的方法
US20190023809A1 (en) * 2015-09-03 2019-01-24 The Children's Mercy Hospital Anti-nicotinamide phosphoribosyltransferase antibody genes and methods of use thereof
IL312251A (en) 2015-10-02 2024-06-01 Hoffmann La Roche Bispecific anti-human cd20/human transferrin receptor antibodies and methods of use
AR106189A1 (es) 2015-10-02 2017-12-20 Hoffmann La Roche ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO
PT3374392T (pt) * 2015-11-13 2022-02-07 Ablynx Nv Domínios variáveis de imunoglobulina que se ligam a albumina sérica melhorados
RU2018138122A (ru) 2016-04-05 2020-05-12 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Новая терапия
US11021527B2 (en) 2017-05-04 2021-06-01 Acceleron Pharma Inc. Transforming growth factor beta receptor type II fusion polypeptides
GB201807693D0 (en) * 2018-05-11 2018-06-27 Autolus Ltd Cell
JP7542799B2 (ja) * 2018-07-04 2024-09-02 京都府公立大学法人 眼組織の線維化抑制用組成物
CN114173806A (zh) * 2019-07-26 2022-03-11 密歇根州立大学董事会 预防或治疗骨骼肌脂肪变性的方法
KR20220117267A (ko) 2019-12-24 2022-08-23 메뤼스 엔.페. Tgf-베타-rii 결합 단백질
KR102314157B1 (ko) * 2020-01-10 2021-10-19 주식회사 뉴클릭스바이오 TGF-β 수용체에 특이적으로 결합하는 항체 및 이의 이용방법
WO2022099090A1 (en) * 2020-11-06 2022-05-12 Xencor, Inc. Heterodimeric antibodies that bind tgfbrii
IL305181A (en) 2021-02-15 2023-10-01 Takeda Pharmaceuticals Co Cell therapy compositions and methods for modulating tgf-b signaling

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
IL127127A0 (en) 1998-11-18 1999-09-22 Peptor Ltd Small functional units of antibody heavy chain variable regions
JP2001206899A (ja) 1999-11-18 2001-07-31 Japan Tobacco Inc ＴＧＦ−βＩＩ型受容体に対するヒトモノクローナル抗体及びその医薬用途
US20050089932A1 (en) 2001-04-26 2005-04-28 Avidia Research Institute Novel proteins with targeted binding
US20050053973A1 (en) 2001-04-26 2005-03-10 Avidia Research Institute Novel proteins with targeted binding
EP1399484B1 (en) 2001-06-28 2010-08-11 Domantis Limited Dual-specific ligand and its use
AU2003210806A1 (en) 2002-03-05 2003-09-22 Eli Lilly And Company Heterologous g-csf fusion proteins
US9321832B2 (en) 2002-06-28 2016-04-26 Domantis Limited Ligand
US7696320B2 (en) 2004-08-24 2010-04-13 Domantis Limited Ligands that have binding specificity for VEGF and/or EGFR and methods of use therefor
SI1517921T1 (sl) 2002-06-28 2006-10-31 Domantis Ltd Dvojno-specificni ligandi z zvisano serumsko razpolovno dobo
US20060002935A1 (en) 2002-06-28 2006-01-05 Domantis Limited Tumor Necrosis Factor Receptor 1 antagonists and methods of use therefor
EP1900753B1 (en) 2002-11-08 2017-08-09 Ablynx N.V. Method of administering therapeutic polypeptides, and polypeptides therefor
EP1578801A2 (en) 2002-12-27 2005-09-28 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
JP4889493B2 (ja) 2003-05-14 2012-03-07 ドマンティス リミテッド ポリペプチドレパートリーから可逆的にアンフォールドするポリペプチドを回収するための方法
ATE414106T1 (de) 2003-06-30 2008-11-15 Domantis Ltd Pegylierte single-domain-antikörper (dab)
AU2004284090A1 (en) 2003-10-24 2005-05-06 Avidia, Inc. LDL receptor class A and EGF domain monomers and multimers
BRPI0507026A (pt) 2004-02-09 2007-04-17 Human Genome Sciences Inc proteìnas de fusão de albumina
WO2005093074A1 (en) 2004-03-24 2005-10-06 Domantis Limited Gas1 universal leader
GB0418651D0 (en) 2004-08-20 2004-09-22 Medical Res Council Method
US20070012251A1 (en) 2005-07-07 2007-01-18 Martin Zucker Seal arrangement with corrosion barrier and method
US20110159003A1 (en) 2006-01-24 2011-06-30 Domantis Limited Ligands That Bind Il-4 and/or Il-13
GB0724331D0 (en) 2007-12-13 2008-01-23 Domantis Ltd Compositions for pulmonary delivery
JO3096B1 (ar) * 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
MX2012001278A (es) 2009-07-29 2012-03-16 Glaxo Group Ltd Anticuerpos de dominio simple anti-receptor tgf-beta tipo ii.
CA2780221A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
KR101886898B1 (ko) * 2011-01-06 2018-08-08 글락소 그룹 리미티드 Ｔｇｆ-베타 수용체 ｉｉ에 결합하는 리간드

Also Published As

Publication number Publication date
CL2013001975A1 (es) 2014-03-07
CN103443126A (zh) 2013-12-11
CA2823104A1 (en) 2012-07-12
JP2017051191A (ja) 2017-03-16
BR112013016917A2 (pt) 2017-04-04
AU2012204867A8 (en) 2016-03-24
AU2012204867B2 (en) 2016-03-10
KR101886898B1 (ko) 2018-08-08
MX2013007936A (es) 2013-08-09
JP6453289B2 (ja) 2019-01-16
JP6062375B2 (ja) 2017-01-18
ZA201304726B (en) 2014-03-26
US9850307B2 (en) 2017-12-26
PH12013501397A1 (en) 2013-08-28
AU2012204867A1 (en) 2013-07-25
EP2661449A1 (en) 2013-11-13
DOP2013000162A (es) 2014-01-15
WO2012093125A1 (en) 2012-07-12
EP2661449B1 (en) 2017-03-22
NZ612839A (en) 2014-09-26
MA34820B1 (fr) 2014-01-02
CN103443126B (zh) 2016-11-23
AU2016203609A1 (en) 2016-06-16
CO6811807A2 (es) 2013-12-16
PE20140982A1 (es) 2014-08-22
US20180086835A1 (en) 2018-03-29
SG191762A1 (en) 2013-08-30
EA201391012A1 (ru) 2014-01-30
US20150361176A1 (en) 2015-12-17
US9150651B2 (en) 2015-10-06
ES2627299T3 (es) 2017-07-27
JP2014504866A (ja) 2014-02-27
IL227254A0 (en) 2013-09-30
KR20140036146A (ko) 2014-03-25
US20130302335A1 (en) 2013-11-14

Similar Documents

Publication Publication Date Title
CR20130376A (es) Ligandos que se unen al receptor ii del factor de crecimiento transformante-beta
CY1122398T1 (el) Συνδυαστικες θεραπειες με αντισωματα anti-cd38
BR112014019331A2 (pt) anticorpos para cd47 e métodos de uso desses
EA201591750A1 (ru) Антитела против b7-h4 и иммуноконъюгаты
CL2016002455A1 (es) Anticuerpos multiespecíficos.
DK3083694T3 (da) Caniniserede, murine anti-canin-pd-1-antistoffer
MX2015004420A (es) Conjugados del anticuerpo pirrolobenzodiazepina - anti-cd22.
UY34815A (es) Anticuerpos biespecíficos y sus métodos de uso
PE20210648A1 (es) Anticuerpos anti-cd3 y metodos de uso
EA201590993A1 (ru) Гетеродимерные иммуноглобулины
CO7151527A2 (es) Anticuerpos anti-cd79 b e inmunoconjugados
MX2015017331A (es) Anticuerpos anti fc similar a receptor 5 (fcrh5).
UY34206A (es) Anticuerpo monoclonal de interleucina-31
UY34456A (es) Anticuerpos anti-il-36r
MX375020B (es) Anticuerpos anti-alfa-sinucleina y métodos de uso.
MX2015012326A (es) Anticuerpos anti-crth2 y su uso.
UY4151Q (es) Vincha con auriculares
BR112017008945A2 (pt) Anticorpos anti-cs1 e conjugados fármaco- anticorpo
MX2018014178A (es) Anticuerpo anti-fgfr2.
MX372661B (es) Anticuerpos anti-htra1 y metodos de uso.
MX2016004802A (es) Anticuerpos anti-r-espondina (anti-rspo) y metodos de uso.
UY34682A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina.
MX2016004853A (es) Metodos de uso de anticuerpos anti-ly6e.
CL2011002403S1 (es) Luminaria solar.
BR112015023782A2 (pt) conjunto de polias